Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer - moving beyond pathological complete

Serena Di Cosimo1, Grazia Arpino2, Daniele Generali3

  • 1Fondazione IRCCS - Istituto Nazionale Tumori, Milano, Italy.